VR Logo

Opthea Limited (OPT) download report


Healthcare | Biotechnology & Pharma Research

Opthea Limited (OPT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.

IPO Date: 12-Apr-2012

MD, CEO & Exec. Director: Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.

VP of Fin. & Company Sec.: Ms. Karen Adams CPA

Listing: NASDAQ: OPT

Country: Australia

Headquarters: South Yarra, VIC

Website: https://www.opthea.com

Key Facts

Market cap: $281.55 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-56.63 Mln

Cash: $88.27 Mln

Total Debt: $0.07 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $4.73 - 8.73

Shares outstanding: 43,992,400

10 Years Aggregate:

  • CFO: $-130.17 Mln
  • EBITDA: $-167.12 Mln
  • Net Profit: $-115.36 Mln

Stock Performance

Time Period Opthea (OPT) S&P BSE Sensex S&P Small-Cap 600
YTD-11.33-9.18-18.78
1 month-8.98-4.78-8.00
3 months2.61-9.66-13.65
1 Year-15.740.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years9.3111.749.84
As on 01-Jul-2022
Year Opthea (OPT) S&P Small-Cap 600 S&P BSE Sensex
2021-32.7225.2721.99